Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $3.25
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $3.5 to $3.25.
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $3.5 to $3.25.